Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Pasithea Therapeutics Corp - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
KTTA
Nasdaq
8731
https://www.pasithea.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Pasithea Therapeutics Corp
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
- Feb 13th, 2024 12:59 pm
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
- Jan 8th, 2024 12:59 pm
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
- Jan 2nd, 2024 1:35 pm
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
- Dec 28th, 2023 10:00 pm
Pasithea Therapeutics Announces Results from 2023 Annual Meeting
- Dec 19th, 2023 10:19 pm
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models
- Dec 11th, 2023 1:01 pm
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
- Nov 29th, 2023 9:27 pm
Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development
- Nov 29th, 2023 12:59 pm
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS
- Nov 9th, 2023 12:59 pm
Pasithea Therapeutics Corp. Announces Final Results of Tender Offer
- Sep 14th, 2023 12:30 pm
Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
- Sep 7th, 2023 8:14 pm
Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function
- Aug 1st, 2023 11:59 am
Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash
- Jul 20th, 2023 12:43 pm
Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.
- Jul 20th, 2023 12:40 pm
Lucy Scientific Scores Richard Nanula as CEO After Senior Roles at Disney, Amgen, Starwood
- Jul 13th, 2023 1:14 pm
Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors
- Jun 30th, 2023 1:28 pm
Lucy Scientific Discovery Reiterates Its Proposal to Acquire Pasithea Therapeutics Corp.
- Jun 29th, 2023 6:50 pm
Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004
- Jun 29th, 2023 12:29 pm
Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.
- Jun 6th, 2023 8:30 pm
Lucy Scientific Discovery Announces Proposal to Acquire Pasithea Therapeutics Corp.
- Jun 5th, 2023 1:00 pm
Scroll